Abarceo Pharma

Business Services · Sweden · 11-50 Employees

View Company Info for Free

Overview

Headquarters

Park Per Albin Hanssons Vä 41, Malmoe, S...

Revenue

<$5 Million

Industry

Business Services Research & Development
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1

About Abarceo Pharma

Abarceo Pharma is a pre-clinical stage company focused on restoring mitochondrial health, particularly in Type 2 Diabetes (T2D) and other age-related diseases. Founded in 2017 by renowned scientists from Lund University, the company has identified a novel target, VDAC1, which plays a crucial role in beta cell function and energy production. Abarceo is developing a small molecule technology platform aimed at addressing the unmet medical needs in T2D, cardiovascular disease, and Alzheimer's disease, with a market potential exceeding EUR 120 billion. The company aims to establish preclinical proof of concept in various animal models to further explore high-value indications driven by mitochondrial dysfunction.Explore more
Abarceo Pharma's Social MediaPopular SearchesAbarceo PharmaAbarceo Pharma ABSIC Code 87,873NAICS Code 54,541Show more

Is Abarceo Pharma your ideal customer?

Let us give you the heads up on whether it's a good time to reach out

Recommended Actions

Illustration of an envelope

Company Profile Activity

i

Among all Business Services companies

Low Activity

High Activity

Activity Insights

Abarceo Pharma is experiencing very low activity levels compared to other companies in the Business Services sector.

What does this means?

Abarceo Pharma is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Abarceo Pharma.

Abarceo Pharma Tech Stack

A closer look at the technologies used by Abarceo Pharma

Top Business Services Companies

Frequently Asked Questions Regarding Abarceo Pharma

What is Abarceo Pharma's official website?
Abarceo Pharma's official website is www.abarceo.com
What is Abarceo Pharma's Revenue?
Abarceo Pharma's revenue is <$5 Million
What is Abarceo Pharma's SIC code?
Abarceo Pharma's SIC: 87,873
What is Abarceo Pharma's NAICS code?
Abarceo Pharma's NAICS: 54,541
How many employees does Abarceo Pharma have?
Abarceo Pharma has 11-50 employees
What industry does Abarceo Pharma belong to?
Abarceo Pharma is in the industry of: Business Services, Research & Development
What technology does Abarceo Pharma use?
Some of the popular technologies that Abarceo Pharma uses are: WooCommerce, WordPress.org, PHP, Google Font API
What does Abarceo Pharma do?

Abarceo Pharma is a pre-clinical stage company focused on restoring mitochondrial health, particularly in Type 2 Diabetes (T2D) and other age-related diseases. Founded in 2017 by renowned scientists from Lund University, the company has identified a novel target, VDAC1, which plays a crucial role in beta cell function and energy production. Abarceo... is developing a small molecule technology platform aimed at addressing the unmet medical needs in T2D, cardiovascular disease, and Alzheimer's disease, with a market potential exceeding EUR 120 billion. The company aims to establish preclinical proof of concept in various animal models to further explore high-value indications driven by mitochondrial dysfunction.Read More

What are Abarceo Pharma social media links?
Abarceo Pharma Linkedin page
Is Abarceo Pharma a public company?
Abarceo Pharma is private company therefore does not currently have an official ticker symbol
See more information about Abarceo Pharma

Get Started with ZoomInfo

Register for free

Sign Up for Free

Get started for free! No credit card needed. Enjoy up to 25 free contacts each month at no cost.
Elevate your prospecting to the next level

Supercharge Your Prospecting

Search ZoomInfo's database of 106M+ companies and 140M+ professionals to find your next lead.
Expand your business

Grow Your Business

Reveal both personal and business contact details, including emails and phone numbers, and close your most valuable buyers.